FIELD: medicine; pharmaceutics.
SUBSTANCE: present document provides liquid and lyophilised pharmaceutical compositions with adeno-associated virus. According to illustrative aspects, pharmaceutical compositions contain from about 5 mM to about 25 mM L-histidine, from about 0 mM to about 150 mM sodium chloride, from approximately 0.001 % (weight/volume) to approximately 0.01 % (weight/volume) of polysorbate 80 (PS80) and from approximately 1 % to approximately 10 % (weight/volume) of sucrose, trehalose or their combination with AAV. According to illustrative aspects, the pharmaceutical compositions additionally contain glycine or mannitol.
EFFECT: there are presented methods for preparing a pharmaceutical composition containing AAV, methods for treating a blood coagulation disorder in a subject and methods for storing compositions with AAV.
53 cl, 70 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION OF CTLA-4 ANTIBODIES | 2006 |
|
RU2356579C1 |
LIQUID PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2719431C2 |
COMPOSITIONS OF ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2772781C2 |
ANTIBODY COMPOSITION | 2015 |
|
RU2743681C2 |
COMPOSITIONS BASED ON BISPECIFIC ANTIBODIES TO IL-4/IL-13 | 2014 |
|
RU2690850C2 |
LIQUID COMPOSITION OF AN ANTIBODY AGAINST TNF ALPHA | 2018 |
|
RU2756619C2 |
LIQUID COMPOSITION OF POLYPEPTIDES CONTAINING FC DOMAIN OF IMMUNOGLOBULIN | 2011 |
|
RU2600847C2 |
LIPOPEPTIDE COMPOSITION AND RELATED METHODS | 2010 |
|
RU2607526C2 |
VACCINE COMPOSITIONS AGAINST HUMAN PAPILLOMA VIRUS (HPV), CONTAINING ALUMINIUM ADJUVANT, AND METHODS OF PRODUCTION THEREOF | 2012 |
|
RU2610174C2 |
COMPOSITIONS OF ANTIBODIES TO RSV AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2807524C2 |
Authors
Dates
2022-03-29—Published
2017-11-03—Filed